Completed PHASE2 INTERVENTIONAL 1-arm NCT00068432

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Pancreatic Cancer

Interventions Celecoxib Gemcitabine Hydrochloride

Updated 7 times since 2017 Last updated: Oct 30, 2018 Started: Dec 31, 2003 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00068432, this PHASE2 trial focuses on Pancreatic Cancer and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Dayton, United States , Fort Smith, United States , Houston, United States , Kansas City, United States , Orlando, United States , Portland, United States , Racine, United States , Springfield, United States , Urbana, United States and 1 more location